Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Impacts Questionnaire. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
The approval was based on a phase 3 trial showing daridorexant was associated with improved sleep onset, sleep maintenance, and daytime functioning in adults with insomnia.
Ponesimod provides clinical benefit over teriflunomide for fatigue among patients with relapsing multiple sclerosis regardless of disease activity status.
Idorsia Pharmaceuticals Ltd: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021 2021 Idorsia Ltd (SIX: IDIA) today announced that nine abstracts for daridorexant, the company's investigational dual orexin receptor antagonist for the treatment of adults with insomnia, will be presented at SLEEP 2021. The annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society is conducted virtually from June 10-13. Antonio Olivieri, Senior Vice President , Head of Global Medical Affairs of Idorsia commented: "As a company with a strong scienti...
Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021